A key target for these therapies is a protein called CD19 found on the cancer cells," added Dr. Chen, corresponding author of the new study. However, in 28–68% of cases, the cancer cells lower ...

Aleta’s approach is based on CD19 CAR T-cell engagers (CTEs), simple but potent proteins designed to enhance the expression of CAR T-cell target antigens on any tumor cell. CTEs contain multiple ...